Unlocking the Key to Neurodegenerative Diseases: In-Depth Analysis of Target MAPT and the Tet-On Precision Regulation System

Share:

In the mysterious universe of the brain, countless neurons rely on a precise “cytoskeleton” to maintain their shape and function. When a key protein—the “Tau protein” (encoded by the MAPT gene)—malfunctions, it can trigger a series of devastating neurodegenerative diseases such as Alzheimer’s. Today, we will dive into this critical target MAPT and unveil a powerful research tool—the Tet-On inducible system—to see how they work together, bringing new light to solving the brain’s mysteries.

Tau protein is a critical microtubule-associated protein that maintains neuronal stability. When the MAPT gene mutates (commonly studied mutations in research include P301S or P301L) or the protein undergoes abnormal modifications, Tau protein can go out of control, directly leading to a class of diseases called “tauopathies.” We can visualize it as the cell’s internal “bridge engineer.” Its main function is to bind and stabilize the cell’s “skeleton” and “transport highways”—the microtubules. These microtubule structures are crucial for maintaining the unique shape of neurons (such as long axons) and for transporting nutrients via “molecular trucks.” Without properly functioning Tau protein, microtubules become unstable, causing structural collapse and transport system failure.

文章内容
Figure 1: Function of Tau protein

The gene responsible for encoding human Tau protein (MAPT gene) is located on chromosome 17. It consists of 16 exons, with exons 0 and 14 transcribed but untranslated. Alternative splicing of MAPT produces six main Tau isoforms in the adult human brain. Tau protein is classified as an intrinsically disordered protein (IDP) due to its lack of a defined three-dimensional structure. Unlike most proteins that fold into a specific conformation to function, Tau proteins, despite being IDPs and lacking a defined structure, possess high flexibility, allowing them to adopt multiple conformations.

文章内容
Figure 2: Schematic of 6 Tau isoforms produced by alternative slicing of the Tau gene

To study how MAPT mutations lead step by step to cellular pathology, we need a tool that can control gene expression at specific times and levels. The Tet-On inducible expression system is such a “gene switch.” Its working principle is simple:

  1. “Off” state: Under normal conditions, the MAPT mutant gene introduced into cells (e.g., P301S) is completely silent, leaving the cell like a blank canvas.
  2. “On” command: When we add a safe small molecule drug—Doxycycline—to the culture medium, it acts like a key, activating the switch inside the cell.
  3. Precise expression: The switch is activated, and the MAPT mutant gene begins transcription and translation, producing the mutant Tau protein we want to study.

The system’s greatest advantage is the ability to control protein expression timing, regulate protein levels, and create perfect controls by adding or withholding Doxycycline, providing a powerful tool for MAPT research.

文章内容
Figure 3: Working principle of the Tet-On system

Uncontrolled Tau protein leads to neurodegenerative diseases. Beyond Alzheimer’s disease, frontotemporal dementia, progressive supranuclear palsy, and other conditions are directly related to Tau pathology. Therefore, MAPT research has become one of the forefront areas in neuroscience. Current MAPT-targeted drug candidates include:

文章内容

To advance neurodegenerative disease treatment, Kyinno Biotechnology has developed Tet-On-regulated MAPT mutant gene overexpression engineered cell lines. These not only successfully overexpress MAPT mutant genes (P301S and P301L) in CHOK1 cells but also integrate the Tet-On inducible expression system, enabling precise control of MAPT mutant gene expression. Fine-tuned regulation of Tau protein levels can be achieved by adjusting Doxycycline dosage. In preclinical studies, these engineered cells provide a robust foundation for simulating disease progression, avoiding toxicity from constitutive expression, and conducting dose-response studies.

In addition to cell line construction services, Kyinno Biotechnology also provides antibody discovery, antibody expression, off-target antibody screening, and in vivo and in vitro pharmacology testing services. Contact us for more information.

List of MAPT Overexpression Engineered Cell Lines:

  • KC-4553 CHOK1-Tet-on-MAPT-P301S-Low
  • KC-4943 CHOK1-Tet-on-MAPT-P301S
  • KC-4552 CHOK1-Tet-on-MAPT-P301L-Low
  • KC-4913 CHOK1-Tet-on-MAPT-P301L

Validation Data:

KC-4553 CHOK1-Tet-on-MAPT-P301S-Low KC-4943 CHOK1-Tet-on-MAPT-P301S

文章内容

KC-4552 CHOK1-Tet-on-MAPT-P301L-Low KC-4913 CHOK1-Tet-on-MAPT-P301L

文章内容